CeriBell (NASDAQ:CBLL) Stock: Insider William Burke Sells 18,000 Shares

CeriBell, Inc. (NASDAQ:CBLL) Director William Burke sold 18,000 shares of the company’s stock in a transaction on Thursday, November 12th. The shares were sold at an average price of $26.64, for a total transaction of $479,520.00. Following the completion of the sale, the director directly owned 23,022 shares in the company, valued at $613,306.08. This represents a 43.88% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link.

CeriBell Stock Down 0.8%

NASDAQ CBLL traded down $0.21 during trading hours on Friday, reaching $26.14. 267,634 shares of the company traded hands, compared to its average volume of 590,859. The stock has a market capitalization of $1.02 billion, a PE ratio of -13.47 and a beta of 0.86. The company has a current ratio of 8.18, a quick ratio of 7.79 and a debt-to-equity ratio of 0.17. CeriBell, Inc. has a 12 month low of $12.40 and a 12 month high of $28.89. The company has a 50 day moving average of $25.52 and a two-hundred day moving average of $21.04.

CeriBell (NASDAQ:CBLL) last issued its earnings results on Tuesday, November 3rd. The company reported ($0.55) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.51) by ($0.04). The company had revenue of $29.34 million during the quarter, compared to analyst estimates of $29.18 million. CeriBell had a negative net margin of 67.96% and a negative return on equity of 52.59%. As a group, equities analysts expect that CeriBell, Inc. will post -2.05 earnings per share for the current year.

Hedge Funds Weigh In On CeriBell

Institutional investors have recently made changes to their positions in the stock. Entropy Technologies LP acquired a new stake in shares of CeriBell during the 3rd quarter worth approximately $803,000. Jump Financial LLC boosted its position in CeriBell by 153.2% during the 3rd quarter. Jump Financial LLC now owns 93,705 shares of the company’s stock valued at $2,285,000 after purchasing an additional 56,702 shares during the period. Lisanti Capital Growth LLC bought a new position in CeriBell during the 3rd quarter worth $4,466,000. Squarepoint Ops LLC bought a new position in CeriBell during the 2nd quarter worth $638,000. Finally, Wellington Management Group LLP grew its stake in CeriBell by 5.5% during the 2nd quarter. Wellington Management Group LLP now owns 87,698 shares of the company’s stock worth $1,706,000 after buying an additional 4,572 shares during the last quarter.

Analyst Ratings Changes

A number of research analysts have commented on CBLL shares. TD Cowen increased their target price on CeriBell from $29.00 to $33.00 and gave the stock a “buy” rating in a report on Friday, October 2nd. Barclays upgraded CeriBell to a “neutral” rating in a report on Tuesday, August 18th. Canaccord Genuity Group upped their price target on CeriBell from $26.00 to $33.00 and gave the company a “buy” rating in a research report on Wednesday, November 4th. BTIG Research restated a “buy” rating on shares of CeriBell in a research note on Wednesday, November 4th. Finally, Raymond James Financial reaffirmed a “strong-buy” rating and issued a $29.00 price objective on shares of CeriBell in a report on Thursday, September 3rd. One investment analyst has rated the stock with a Strong Buy rating, three have assigned a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat, CeriBell currently has an average rating of “Moderate Buy” and an average price target of $31.25.

About CeriBell

Ceribell, Inc. develops neurodiagnostic technology for detecting and monitoring seizures. Its products are designed to make electroencephalography (EEG) more accessible in emergency departments and intensive care units, where timely assessment can be important and conventional EEG services may not be readily available. The company’s Ceribell point-of-care EEG system combines a headband with electrodes, a portable recorder and software for viewing and analyzing EEG data. Its Clarity algorithm is designed to help clinicians identify patterns associated with seizure activity, while the system supports remote review by specialists.